T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (208)	8/10/2000 3:10:22 PM
From: ahhaha	Read Replies (1) of 2243

MDCC is a viable 30% grower with a visible earnings stream. The recent acquisition of LJL strengthens their technological position. Whereas fluorescence based assay technologies may not be as cutting edge as LMNX's laser beads, it's solid and cost effective once the initial cost is swallowed. The LJL division is approaching the inflect of a renewable cycle and will start to reflect new buying decisions next year. How MDCC will handle this remains to be seen. Nonetheless, if one wants to be invested in some part of drug discovery and they don't want the risk of the "10 baggers", MDCC would be a good choice. It's the kind of deal that you find sneaks up on you. The stock like most is selling off and will be putting in a good bottom in coming months. When it does so and proves the bottom by building a base, one should look for a break out from that base for a good entry into a long term performer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next